Targeting Non-Oncogene Addiction for Cancer Therapy

Area of Science:

• Oncology
• Molecular Biology
• Genetics

Background:

• Cancer remains a significant global health challenge despite advances in Next-Generation Sequencing (NGS).
• DNA replication, DNA damage response (DDR), and cell cycle regulation are critical processes in cancer development and are key targets for therapy.
• Cancer cells often exhibit addiction to genes involved in DDR, even those typically acting as tumor suppressors, creating therapeutic vulnerabilities.

Purpose of the Study:

• To review genes involved in DNA replication, DDR, DNA repair, and cell cycle regulation for targeted cancer therapy.
• To explore the potential of synthetic lethality in identifying novel therapeutic targets within these pathways.
• To evaluate the potential of TONSL as a novel target for cancer therapy.

Main Methods:

• Literature review of genes in DNA replication, DDR, DNA repair, and cell cycle regulation.
• Analysis of peptide and small molecule inhibitors targeting these pathways.
• Examination of synthetic lethal interactions and their application in cancer therapy.
• Evaluation of TONSL as a potential therapeutic target, drawing parallels with PCNA inhibitor strategies.

Main Results:

• Genes involved in DNA replication, DDR, and cell cycle regulation are crucial for cancer cell survival and represent viable therapeutic targets.
• Synthetic lethality offers a promising strategy for developing novel cancer therapeutics by exploiting specific genetic vulnerabilities.
• TONSL, a scaffold protein, is identified as a potential novel target, with strategies for PCNA inhibitor development being applicable.

Conclusions:

• Targeting non-oncogene addiction pathways, particularly those involving DNA repair and cell cycle regulation, is a viable strategy for cancer therapy.
• Synthetic lethality provides a powerful framework for discovering and developing new targeted cancer drugs.
• TONSL represents a promising new target for developing innovative cancer therapeutics.